Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Immunomodulatory role of nonneuronal cholinergic signaling in myocardial injury
Cibele Rocha-Resende, Carla Weinheimer, Geetika Bajpai, Luigi Adamo, Scot J. Matkovich, Joel Schilling, Philip M. Barger, Kory J. Lavine, Douglas L. Mann
Cibele Rocha-Resende, Carla Weinheimer, Geetika Bajpai, Luigi Adamo, Scot J. Matkovich, Joel Schilling, Philip M. Barger, Kory J. Lavine, Douglas L. Mann
View: Text | PDF
Research Article Cardiology Inflammation

Immunomodulatory role of nonneuronal cholinergic signaling in myocardial injury

  • Text
  • PDF
Abstract

Whereas prior studies have demonstrated an important immunomodulatory role for the neuronal cholinergic system in the heart, the role of the nonneuronal cholinergic system is not well understood. To address the immunomodulatory role of the nonneuronal cholinergic system in the heart, we used a previously validated diphtheria toxin–induced (DT-induced) cardiomyocyte ablation model (Rosa26-DTMlc2v-Cre mice). DT-injected Rosa26-DTMlc2v-Cre mice were treated with diluent or pyridostigmine bromide (PYR), a reversible cholinesterase inhibitor. PYR treatment resulted in increased survival and decreased numbers of MHC-IIloCCR2+ macrophages in DT-injected Rosa26-DTMlc2v-Cre mice compared with diluent-treated Rosa26-DTMlc2v-Cre mice. Importantly, the expression of CCL2/7 mRNA and protein was reduced in the hearts of PYR-treated mice. Backcrossing Rosa26-DTMlc2v-Cre mice with a transgenic mouse line (Chat-ChR2) that constitutively overexpresses the vesicular acetylcholine transporter (VAChT) resulted in decreased expression of Ccl2/7 mRNA and decreased numbers of CD68+ cells in DT-injured Rosa26-DTMlc2v-Cre/Chat-ChR2 mouse hearts, consistent with the pharmacologic studies with PYR. In vitro studies with cultures of LPS-stimulated peritoneal macrophages revealed a concentration-dependent reduction in CCL2 secretion following stimulation with acetylcholine, nicotine, and muscarine. To our knowledge, these findings reveal a previously unappreciated immunomodulatory role for the nonneuronal cholinergic system in regulating homeostatic responses in the heart following tissue injury.

Authors

Cibele Rocha-Resende, Carla Weinheimer, Geetika Bajpai, Luigi Adamo, Scot J. Matkovich, Joel Schilling, Philip M. Barger, Kory J. Lavine, Douglas L. Mann

×

Figure 6

Effect of VAChT overexpression in the heart following diphtheria toxin–mediated injury.

Options: View larger image (or click on image) Download as PowerPoint
Effect of VAChT overexpression in the heart following diphtheria toxin–m...
(A) Vacht mRNA levels in the hearts of littermate (LM), Chat-ChR2 mice, diphtheria toxin–injected (DT-injected) Rosa26-DTMlc2v-Cre (Rosa26-DT), and Rosa26-DTMlc2v-Cre/Chat-ChR2 mice on day 3 after DT injection (n = 5–10 hearts/group). (B) Representative VAChT immunofluorescence staining in DT-injected (day 3) Rosa26-DTMlc2v-Cre and Rosa26-DTMlc2v-Cre/Chat-ChR2 hearts. Scale bar: 20 μm. (C) Group data of VAChT expression by immunofluorescence staining in DT-injected (day 3) Rosa26-DTMlc2v-Cre and Rosa26-DTMlc2v-Cre/Chat-ChR2 hearts (n = 3 hearts/condition). (D and E) Ccl2 and Ccl7 mRNA expression in the hearts of DT-injected (day 3) LM, Chat-ChR2, Rosa26-DTMlc2v-Cre, and Rosa26-DTMlc2v-Cre/Chat-ChR2 mice (n = 3–10 hearts/group). (F) Representative immunofluorescence staining of CD68+ cells in DT-injected Rosa26-DTMlc2v-Cre and Rosa26-DTMlc2v-Cre/Chat-ChR2 hearts on day 5 after DT administration. Scale bar: 50 μm. (G) Group data of CD68+ cells in DT-injected Rosa26-DTMlc2v-Cre and Rosa26-DTMlc2v-Cre/Chat-ChR2 hearts on day 5 after DT injection (n = 4 hearts/group). *P < 0.05 in comparison with LM, †P < 0.05 in comparison with Rosa26-DTMlc2v-Cre/Chat-ChR2. P values were calculated with 1-way ANOVA followed by the Tukey post hoc test for A, D, and E and Student’s t test for C and G.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts